Opioid Use Disorder: Treatment With Injectable & Implantable Buprenorphine

Account Registration

Already a member?

"*" indicates required fields

Step 1 of 3

Username

Name

Password*

Strength indicator

Recommendations: at least 12 characters in length, include a mix of character types (uppercase, lowercase, numbers, special characters %$^&), do not use common words or phrases

Organization

Occupation Category*

Address

This field is hidden when viewing the form

occupational_category_audience_kdm

This field is hidden when viewing the form

occupational_category_audience_kdm

Opioid Use Disorder: Treatment With Injectable & Implantable Buprenorphine

July 18, 2025

In August 2020, the U.S. Government Accountability Office (ACO) published a report focused on injectable and implantable controlled substances that can be used to treat opioid use disorder (OUD), and specifically, describes the process for treating OUD with injectable and implantable buprenorphine and what is known about their use.

Want To Read More?

This content is exclusive to RECADEMY members.

RECADEMY is a comprehensive, research-based, online learning collaborative designed to provide critical information about emerging substance use disorder treatment topics and models of care.

Sign in or join the RECADEMY community for free today.

Opioid Use Disorder: Treatment With Injectable & Implantable Buprenorphine

Recent Resources

RECADEMY Webinar Explores Treating Opioid Use Disorder As A Chronic Brain Disease

Treating Fentanyl & High-Potency Synthetic Opioid (HPSO) Use Disorder: Evidence-Based MOUD Protocols, Induction Strategies, & Harm Reduction Approaches in Real-World Care Settings

RECADEMY Webinar Examines How Fentanyl Is Reshaping Opioid Use Disorder Treatment

What’s Working in OUD Treatment & System Transformation: The ROI of MOUD for Health Systems, Payers & Communities

Opioid Use Disorder: Treatment With Injectable & Implantable Buprenorphine

Recent Resources

Related